DOI: https://doi.org/10.22141/2224-0713.7.101.2018.149662

Clinical and neurological peculiarities and pathogenetic mechanisms of tau protein involvement in the axonal brain damage and neurodegeneration

Ye.V. Lekomtseva

Abstract


This investigation was carried out to study the content of microtubule-associated tau protein in sera of 42 patients with different neurodegenerative disorders (mean age of patients was 58.31 ± 13.49 years), among them there were eight patients with Alzheimer’s disease (mean age 69.76 ± 9.50 years), primary-generalized pharmacoresistant epilepsy (n = 23, mean age 40.95 ± 7.3 years) and Parkinson’s disease, tremor form (n = 11, mean age 51.38 ± 12.61 years), healthy controls (n = 30, mean age 42.11 ± 5.67 years). In this work for tau protein evaluation, immunofluorescence method was used with the primary and secondary monoclonal antibodies (SIGMA, USA). It was shown that tau protein content is evenly increased in almost all patients with neurodegenerative pathology, regardless of its course, with a tendency to higher values in patients with Alzheimer’s disease. Identification of tau protein may serve as a non-specific marker of axonal damage that accompanies various types of neurodegeneration.


Keywords


tau protein; neurodegeneration; axonal brain damage

References


Болезни нервной системы: В 2 т. / Под ред. Н.Н. Яхно, Д.Р. Штульмана. — М.: Медицина, 2001. — 480 с.

Ворлоу Ч.П., Деннис М.С., Гейн Ж.В. Инсульт. Практическое руководство для ведения больных: Пер. с англ. — СПб.: СП «Политехника», 1998. — 629 с.

Зенков Л.Р. Клиническая эпилептология (с элементами нейрофизиологии). — М.: Медицинское информационное агентство, 2002. — 416 с.

Иванов Ю.И., Погорелюк О.Н. Обработка результатов медико-биологических исследований на микрокалькуляторах. — М.: Медицина, 1990. — 218 с.

Avila J., Lucas J., Perez M., Hernandez P. Role of Tau Protein in both physiological and pathological conditions // Physiol. Rev. — 2004. — Vol. 84. — P. 361-384.

Bartosik-Psuiek H., Stelmasiak Z. The CSF levels of total-tau and phosphor-tau in patients with relapsing-remitting multiple sclerosis // J. Neural. Transm. — 2006. — 113. — P. 339-345.

Blennow K., Zetterberg H. // Alzheimer Disease Lancet. — 2006. — 368. — P. 387-403.

Bulut M., Koksal O., Dogan S. et al. Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results // Advances in Therapy. — 2006. — № 23(1). — Р. 12-22.

Delacourte A. Tauopathies: recent insights into old diseases // Folia Neuropathol. — 2005. — № 43. — Р. 244-257.

Kapaki E., Paraskevaz G., Michalopoulou M., Kilidireas K. Increased cerebrospinal luid tau protein in multiple sclerosis // Eur. Neurol. — 2000. — № 43(4). — P. 228-232.

Lekomtseva Y., Gorbach T., Gubina-Vakulik G. High serum tau protein in patients with therapy-resistant intractable epilepsy under a baseline // J. of Neurology. — 2009. — Vol. 256(Suppl. 2). — P. S77.

Roder H.M., Hutton M.L. Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease // Expert Opin. Ther. Targets. — 2007. — № 11(4). — Р. 435-442.

Terzi M., Birinci A., Cetinkaya E., Onar M.K. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis // Acta Neurol. Scand. — 2007. — 115(5). — Р. 325-30.

Uchihara T., Duyckaerts C., Seilhean D. et al. Exclusive induction of tau2 epitope in microglia/macrophages in inflammatory lesions-tautwopathy distinct from degenerative tauopathies // Acta Neuropathol. — 2005. — 109. — P. 159-164.

Zemlan P.F. US Patent 6589746. Method of detecting axonally-derived protein tau in patients with traumatic CNS injury // Traumatic CNS injury. — 2003.




Copyright (c) 2019 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта